AstraZeneca PLC (AZN)vsGuardian Pharmacy Services, Inc. (GRDN)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
GRDN
Guardian Pharmacy Services, Inc.
$40.48
-0.78%
HEALTHCARE · Cap: $2.73B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4051% more annual revenue ($60.44B vs $1.46B). AZN leads profitability with a 17.2% profit margin vs 3.6%. AZN trades at a lower P/E of 27.5x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
GRDN
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for GRDN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Conservative balance sheet, low leverage
Earnings expanding 39.0% YoY
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 11.6x book value
2.2% revenue growth
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : GRDN
The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : GRDN
The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 51.3x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while GRDN is a value play — different risk/reward profiles.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 50/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Guardian Pharmacy Services, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, serving assisted living and skilled nursing facilities. The company is recognized for its commitment to personalized medication management, high standards of quality and compliance, and superior customer service. By utilizing advanced technology and deep pharmaceutical expertise, Guardian not only improves patient outcomes but also streamlines operations for healthcare partners. With a substantial operational presence in multiple states, Guardian is well-equipped to address the growing demand for tailored pharmacy services in a rapidly evolving healthcare environment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?